Product Explainer

Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted

Description

In this Product Explainer Geriatrician A/Prof Michael Woodward AM explains an adjuvanted vaccine indicated for the active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).1

Reference: 1. AREXVY Product Information

This video was developed by Heathed with funding from GSK.
Views of the speaker are their own and do not necessarily reflect that of GSK. GSK recommends usage in accordance with the Product Information.

PM-AU-RSA-WCNT-240007 Date of approval: March 2024.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Shannon Thomas

Dr Shannon Thomas

TIAs and Carotid Stenosis

Dr Ginni Mansberg

Dr Ginni Mansberg

HSDD - What is it & How is it Managed?

Dr Rupert Hinds

Dr Rupert Hinds

Functional Gastrointestinal Disorders in Infants – Practical Advice for HCPs

A/Prof Michael Woodward AM

A/Prof Michael Woodward AM

Using the New RSV Vaccine in Practice

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

A/Prof Michael Woodward AM

expert

A/Prof Michael Woodward AM

Geriatrician; Head of Aged Care and Memory Clinic, Austin Health

Date published: 9 March 2024